Colorado spin-out on tract

Colorado University has granted its fresh spin-out EnteroTrack an exclusive license to develop and commercialise a device which will monitor inflammation of the gastrointestinal tract.

Currently, monitoring conditions such as gastroesophageal reflux or inflammatory bowel disease are tricky, and often require an invasive endoscopy procedure to identify the cause or extent of a condition. EnteroTrack will be looking to offer an alternative method of diagnosis in the form of a small capsule which can provide accurate and low-cost analysis of conditions.

Robin Shandas, interim CEO at EnteroTrack, said: “Given the increasing pressures to contain costs, there is clear rationale for innovative, cost-effective methods to monitor esophageal diseases. This technology holds particular promise because it can reduce total patient care costs while keeping good margins. We hope to obtain FDA approval for the device in 2015.”